ORGANIZATION

• Japan at a Crossroads as Investment Destination, World’s Eyes Riveted on Govt’s Signals: PhRMA Local Chief
  April 13, 2016

• EFPIA Japan Chief to Call for “Real Dialogue” at Today’s Public-Private Policy Confab
  April 12, 2016

• Asian Industry Groups Agree to Continue Efforts to Improve Access to Innovative Medicines in Asia
  April 11, 2016

• Front-Loaded Price Cuts Necessary for Drugs Like Opdivo: JMA’s Nakagawa
  April 7, 2016

• Japan Pharma Groups Step Up Lobbing Campaigns to Skirt Further Drug Cost Cuts
  April 7, 2016

• Generic Use Rate at 56.1% in October-December 2015: JGA
  April 1, 2016

• JPMA Issues Notification Urging Member Companies to Strengthen Internal Ad Review Systems
  March 25, 2016

• FPMAJ Braced for Thorny Path Ahead Even If Sales Tax Postponed, Revenue Falls Would Weigh on Industry: Chief
  March 18, 2016

• Discuss Role of Drugs in Overall Social Security System: Full Interview with FPMAJ Pricing Affairs Chief
  March 18, 2016

• “Huge-Seller” Re-Pricing Eroding Predictability of Japanese System: FPMAJ’s Kamoya
  March 10, 2016

• PhRMA Japan Committee Sets Out Guiding Principles for MSLs
  February 26, 2016

• FY2016 Reimbursement Policy Reform “Tough” on Industry: JPMA
  February 19, 2016

• Top MHLW Bureaucrat Says 80% Generic Share “Achievable”
  February 16, 2016

• Former JMA Pres. Eitaka Tsuboi Dies at 86
  February 15, 2016

• EFPIA Japan Lays Out Basic Principles on MSL Activities
  February 4, 2016

• Japanese Pharma Market to Shrink 30% over 10 Years with Annual Revisions: New PhRMA Japan Chief
  January 22, 2016

• JPMA Expels Kaketsuken over GMP Violations, Cover-Up
  January 22, 2016

• PhRMA Japan Representative Ira Wolf Dies at 70
  January 19, 2016

• JPMA Head Hints “Free Pricing” Could Be an Option in System Overhaul
  January 18, 2016

• JPMA Unveils Pharma Industry Vision 2025
  January 18, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 47
• 48
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• …
• Next ›
• 最終 »